These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9951331)

  • 1. [Efficacy of seroconversion and duration of immunity induced by the meningococcal serogroup C vaccine. Study included in the evaluation of the mass immunization of the population in the age group between 18 months and 19 years in the community of Madrid].
    Ramírez Fernández R
    Rev Esp Salud Publica; 1998; 72(5):401-6. PubMed ID: 9951331
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bactericidal activity against Neisseria meningitidis serogroup C in the vaccinated and non-vaccinated population of Andlucía].
    Delgado Torralbo E; Berrón Morato S; García León J; González Enríquez J; Martinez Navarro F
    Rev Esp Salud Publica; 1998; 72(5):407-10. PubMed ID: 9951332
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the campaign on vaccination against meningococcal disease in Galicia. Methodology, advantages and disadvantages, Study of carriers].
    Malvar Pintos A
    Rev Esp Salud Publica; 1998; 72(5):393-400. PubMed ID: 9951330
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effectiveness of seroconversion of the Neisseria meningitidis serogroup C vaccine, duration of antibody levels in the Autonomic Community of Extremadura].
    Ramos Aceitero JM
    Rev Esp Salud Publica; 1998; 72(5):411-4. PubMed ID: 9951333
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methodology of the study of pre- and post-vaccination antibodies against serogroup C Meningococcus].
    Espín Ríos I; García Fulgueiras A; Vázquez Moreno J; Navarro Sánchez C; Rodríguez González T; Navarro Alonso JA; Pérez Flores D
    Rev Esp Salud Publica; 1998; 72(5):419-22. PubMed ID: 9951335
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effectiveness of the massive campaign for immunization against Meningococcus (serogroup C) in the Autonomic Community of the Basque Province].
    Elexpe Uriarte X
    Rev Esp Salud Publica; 1998; 72(5):423-30. PubMed ID: 9951336
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of vaccine in meningococcal disease in Cantabria].
    González de Aledo Linos A; García Merino J
    Rev Esp Salud Publica; 1998; 72(5):415-8. PubMed ID: 9951334
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Seroprevalence of bactericidal anti-meningococcal antibodies in Cantabria 10 months following a vaccination campaign].
    González de Aledo Linos A; García Merino J
    Rev Esp Salud Publica; 1998; 72(4):365-74. PubMed ID: 9810841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of meningococcal infection among infant population in the autonomous community of Valencia (1996-2000). Effectiveness of A+C meningococcal vaccination].
    Goicoechea Sáez M; Fullana Montoro AM; Momparler Carrasco P; Redondo Gallego MJ; Brines Solanes J; Bueno Cañigral FJ
    Rev Esp Salud Publica; 2003; 77(1):125-42. PubMed ID: 12696392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).
    Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA;
    Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
    Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
    Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Meningococcal disease. The situation in Spain in the 1998-1999 period].
    Cano Portero R; García Delgado C; de Mateo Ontañón S
    Rev Esp Salud Publica; 2000; 74(4):369-75. PubMed ID: 11031845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
    McVernon J; MacLennan J; Pollard AJ; Oster P; Wakefield MJ; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2003 Jul; 22(7):659-61. PubMed ID: 12886896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.